Dr. Guido A. Davidzon is a physician-scientist board certified in Nuclear Medicine. He graduated with honors from medical school in Argentina and completed an internship at Yale University New-Haven Hospital in Connecticut. He did his residency and was chief resident at Stanford Health Care. He completed a research fellowship in mitochondrial diseases at Columbia University in New York and, a U.S. National Library of Medicine Award supported, Biomedical Informatics fellowship at Massachusetts General Hospital in conjunction with a Science Masters at MIT.
Dr. Davidzon is Clinical Assistant Professor in the Department of Radiology at Stanford University and Boston University School of Medicine. His clinical specialties include early diagnostic imaging of cancer, coronary artery disease, and dementias using molecular probes as well as the treatment of cancer for which he employs targeted radiopharmaceutical therapy.
Dr. Davidzon investigates the use of machine learning in medical imaging to improve clinical outcomes, he is involved in the professional Society of Nuclear Medicine and Molecular Imaging. He serves as a peer reviewer for multiple medical journals. Dr. Davidzon is a native of Buenos Aires, Argentina and has lived in the U.S. for over a decade. He travels to Argentina frequently, with his wife and three sons.
Kaiser Permanente Santa Clara Medical Center
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 57 results.
Hall JN, Mormino E, Ng A, Boumis A, Gaudioso JL, Davidzon GA, Sha SJ. Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab. JAMA Neurol. 2022 Jan 01; 79(1):87-89. PMID: 34747986
Duan H, Baratto L, Hatami N, Liang T, Mari Aparici C, Davidzon GA, Iagaru A. 68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. Transl Oncol. 2022 Jan; 15(1):101293. PMID: 34823095
Chaudhari AS, Mittra E, Davidzon GA, Gulaka P, Gandhi H, Brown A, Zhang T, Srinivas S, Gong E, Zaharchuk G, Jadvar H. Author Correction: Low-count whole-body PET with deep learning in a multicenter and externally validated study. NPJ Digit Med. 2021 Sep 14; 4(1):139. PMID: 34521985; PMCID: PMC8440668; DOI: 10.1038/s41746-021-00512-6;
Beinat C, Patel CB, Haywood T, Murty S, Naya L, Castillo JB, Reyes ST, Phillips M, Buccino P, Shen B, Park JH, Koran MEI, Alam IS, James ML, Holley D, Halbert K, Gandhi H, He JQ, Granucci M, Johnson E, Liu DD, Uchida N, Sinha R, Chu P, Born DE, Warnock GI, Weissman I, Hayden-Gephart M, Khalighi M, Massoud TF, Iagaru A, Davidzon G, Thomas R, Nagpal S, Recht LD, Gambhir SS. A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2-Induced Glycolytic Reprogramming in Glioblastoma. Clin Cancer Res. 2021 Dec 01; 27(23):6467-6478. PMID: 34475101; PMCID: PMC8639752; DOI: 10.1158/1078-0432.CCR-21-0544;
Chaudhari AS, Mittra E, Davidzon GA, Gulaka P, Gandhi H, Brown A, Zhang T, Srinivas S, Gong E, Zaharchuk G, Jadvar H. Low-count whole-body PET with deep learning in a multicenter and externally validated study. NPJ Digit Med. 2021 Aug 23; 4(1):127. PMID: 34426629; PMCID: PMC8382711; DOI: 10.1038/s41746-021-00497-2;
Baratto L, Toriihara A, Hatami N, Aparici CM, Davidzon G, Levin CS, Iagaru A. Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors. Diagnostics (Basel). 2021 May 30; 11(6). PMID: 34070751; PMCID: PMC8228776; DOI: 10.3390/diagnostics11060992;
Fite BZ, Hinostroza V, States L, Hicks-Nelson A, Baratto L, Kallianos K, Codari M, Yu B, Jha P, Shams M, Stoyanova T, Chapelin FF, Liu A, Rashidi A, Soto F, Quintana Y, Davidzon GA, Marycz K, Gibbs IC, Chonde DB, Patel CB, Daldrup-Link HE. Increasing Diversity in Radiology and Molecular Imaging: Current Challenges. Mol Imaging Biol. 2021 10; 23(5):625-638. PMID: 33903986; PMCID: PMC8074707; DOI: 10.1007/s11307-021-01610-3;
Eyuboglu S, Angus G, Patel BN, Pareek A, Davidzon G, Long J, Dunnmon J, Lungren MP. Multi-task weak supervision enables anatomically-resolved abnormality detection in whole-body FDG-PET/CT. Nat Commun. 2021 03 25; 12(1):1880. PMID: 33767174; PMCID: PMC7994797; DOI: 10.1038/s41467-021-22018-1;
Baratto L, Song H, Duan H, Hatami N, Bagshaw HP, Buyyounouski M, Hancock S, Shah S, Srinivas S, Swift P, Moradi F, Davidzon G, Iagaru A. PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2021 11; 62(11):1545-1549. PMID: 33674398; PMCID: PMC8612333; DOI: 10.2967/jnumed.120.259630;
Nakamoto R, Zaba LC, Liang T, Reddy SA, Davidzon G, Aparici CM, Nguyen J, Moradi F, Iagaru A, Franc BL. Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy. J Nucl Med. 2021 10; 62(10):1380-1383. PMID: 33547210; DOI: 10.2967/jnumed.120.254482;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.